Eli Lilly And Co (LLY) Coverage Initiated by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Eli Lilly And Co (NYSE:LLY) in a report released on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a hold rating to a buy rating and set a $100.00 price objective for the company in a report on Wednesday, July 18th. TheStreet raised shares of Eli Lilly And Co from a c+ rating to a b rating in a report on Friday, June 29th. Bank of America increased their price objective on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the company a neutral rating in a report on Wednesday, July 25th. Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the company a buy rating in a report on Monday, September 17th. Finally, BMO Capital Markets increased their price target on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a $89.43 rating in a report on Thursday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly And Co currently has an average rating of Buy and a consensus target price of $106.06.

LLY opened at $115.46 on Monday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $116.61. The stock has a market cap of $115.25 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 1.88 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, beating the consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the prior year, the firm earned $1.11 EPS. The business’s revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

In related news, SVP Alfonso G. Zulueta sold 7,000 shares of the stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now directly owns 45,224 shares of the company’s stock, valued at approximately $5,184,479.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the completion of the sale, the insider now directly owns 121,631,601 shares in the company, valued at $11,193,756,240.03. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,770,943 shares of company stock valued at $178,470,135. 0.11% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of LLY. Susquehanna Fundamental Investments LLC purchased a new stake in Eli Lilly And Co in the 1st quarter worth about $3,093,000. A.R.T. Advisors LLC purchased a new stake in Eli Lilly And Co in the 1st quarter worth about $9,586,000. Cornercap Investment Counsel Inc. raised its position in Eli Lilly And Co by 9.2% in the 1st quarter. Cornercap Investment Counsel Inc. now owns 48,471 shares of the company’s stock worth $3,750,000 after purchasing an additional 4,085 shares during the period. The Manufacturers Life Insurance Company raised its position in Eli Lilly And Co by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,413,180 shares of the company’s stock worth $109,337,000 after purchasing an additional 20,788 shares during the period. Finally, Ostrum Asset Management raised its position in Eli Lilly And Co by 68.1% in the 1st quarter. Ostrum Asset Management now owns 97,452 shares of the company’s stock worth $7,545,000 after purchasing an additional 39,472 shares during the period. 76.56% of the stock is currently owned by institutional investors.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Fiduciary

The Fly

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply